Tikosyn Capsules

Company
Pfizer

Approval Status
Approved October 1999

Treatment for
For the maintenance of normal sinus rhythm in patients with atrial fibrillation/atrial flutter.

Areas
Respiratory

Tikosyn (dofetilide) Capsules for the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter [AF/AFl]) in patients with atrial fibrillation /atrial flutter of greater than one week duration who have been converted to normal sinus rhythm. Tikosyn is also indicated for the conversion of atrial fibrillation and atrial flutter to normal sinus rhythm. Tikosyn has not been shown to be effective in patients with paroxysmal atrial fibrillation.

Because Tikosyn can cause life threatening ventricular arrhythmias, it should be reserved for patients in whom atrial fibrillation /atrial flutter is highly symptomatic.

Capsules of dofetilide. Approved interim dissolution method, medium, and specification to be: USP Apparatus I (basket) at 100 rpm in 0.001 M hydrochloric acid; Q=[----] at 30 minutes.

Because Tikosyn can cause life threatening ventricular arrhythmias, it should be reserved for patients in whom atrial fibrillation /atrial flutter is highly symptomatic.

Tikosyn Capsules Drug Information

The Tikosyn Capsules drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Scroll to top